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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not
methylergometrine is more effective than other uterotonic agents in preventing postpartum
hemorrhage during the third stage of labor.
Study Design: Review of two randomized controlled trials (RCTs) published in 2004 and 2009,
and one prospective study published in 2006.
Data Sources: Each article used was published in English and found using PubMed and
Medline. The studies compared the efficacy of methylergometrine against uterotonic agents,
specifically oxytocin and misoprostol.
Outcomes Measured: The efficacy of methylergometrine was measured via the incidence of
postpartum hemorrhage despite the use of prophylactic medication and adverse effects of
medications.
Results: Vimala et al (2004) found that methylergometrine and misoprostol were equally
effective at decreasing the amount of blood loss [170±42ml vs. 185±56ml; p >0.05], as well as in
terms of adverse side effects, specifically nausea [13.3% vs. 6.6%; p >0.05]. Singh et al (2009)
found that methylergometrine was less effective compared to oxytocin in reducing the mean
blood loss during the third stage of labor [223.48ml vs. 154.73ml; p <0.01]. While Fujimoto et
al (2006) also noted that methylergometrine was more likely increase incidences of postpartum
hemorrhage than oxytocin [18.6% vs. 7.3%; OR = 0.31], no differences in resultant adverse side
effects were found [2.8% vs. 1.2%].
Conclusions: Due to the limitations of the studies with regards to the use of methylergometrine
compared to other uterotonic agents, its efficacy over these drugs remains inconclusive.
However, methylergometrine was not shown to produce more adverse side effects than standard
of care uterotonic agents oxytocin and misoprostol.
Key Words: Methylergometrine, oxytocin, misoprostol, postpartum hemorrhage, third stage
labor.
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INTRODUCTION
Postpartum hemorrhage, defined as when a vaginal delivery results in greater than 500ml
of blood loss, is a major cause of maternal death. While it can be attributed to lacerations
sustained during childbirth, retention of products of conception or placental tissue, or defects in
blood coagulation, uterine atony is the preeminent cause of hemorrhage after delivery.
Following the vaginal birth of an infant, the myometrium is responsible for contracting in order
to reduce uterine size and help clamp the vasculature where the placenta implants. However, if
the uterus becomes atonic, the myometrial fibers fail to constrict and continued bleeding from
uterine vessels occurs, which can result in excessive blood loss. Postpartum hemorrhage is the
foremost cause of pregnancy-related mortality in developing countries and is ranked third in the
United States1, with 11.8% of maternal deaths in the US from 2006-2010 resulting from
hemorrhage.2
Considering the potentially life-threatening consequences of labor complications, the
appropriate treatment with regards to postpartum hemorrhage is important to both practitioners
and patients. Since physician assistants are involved in the delivery of infants, knowledge of the
management of labor complications is essential. In all but four states, the extent of obstetrical
care a PA can provide is determined by the supervising physician and hospital regulations. This
means that PAs can be involved in labor and delivery,3 where recognizing and appropriately
treating postpartum hemorrhage is vital.
In 2012, there were 3,952,841 live births in the US.4 Though data on the national
expenditure in cases of maternal hemorrhage are not available, a study limited to California
hospitals performed by UCLA calculated that there is an increased cost of $3,000 per patient. If
severe hemorrhage necessitates hysterectomy, there is an increased cost of $6,403.5 Statistics are
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not available for the number of health care visits attributed to postpartum hemorrhage each year,
but another study based in California found that 2.4% of live births were associated with
postpartum hemorrhage.6
In spite of identifying the cause and risk factors for most postpartum hemorrhage, it is
still difficult to determine which patient will develop hemorrhage. Uterine atony can be
attributed to prolonged labor, undue manipulation or dysfunction of the uterus, uterine fibroids,
augmented labor via oxytocin, or use of general anesthesia. Women whose uterus has undergone
greater distention due to multiple gestation or polyhydramnios are also prone to atony.1
Prophylactic administration of uterotonic agents has been implemented to prevent hemorrhage,
but this method is not infallible, as evidenced by maternal mortality rates. Uterotonic agents are
responsible for stimulating contractions of the uterus, namely in the form of oxytocin,
methylergometrine, or misoprostol.7 These medications are generally administered during the
third stage of labor, or following delivery of the anterior shoulder.8,9,10
Currently, oxytocin and misoprostol are uterotonic agents used for the prevention of
postpartum hemorrhage during the third stage of labor. The gold standard treatment for
postpartum hemorrhage is administration of intravenous oxytocin. Oxytocin has been found to
most effectively minimize the amount of blood loss with the least amount of side effects.
Another option for treatment also includes sublingual administration of misoprostol, which is
effective but associated with more side effects. Although misoprostol is not first line in the
United States, its use has been noted specifically in low resource areas where skilled
practitioners and high tech equipment is not as readily available. Due to these factors, it has
been noted to be a standard of care medication in prevention of postpartum hemorrhage. Since it
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is provided as a sublingual tablet, it does not require training to administer. Additionally, unlike
oxytocin, it does not require refrigeration to maintain its potency.1,7
In the past, methylergometrine has been used as an adjunct therapy if oxytocin has not
been effective in stopping bleeding in cases of postpartum hemorrhage.1 Methylergometrine,
also known as methylergonovine, is an ergot derivative that presents as another one option for
the active management due to its uterotonic properties. It is available as an injection (IV or IM)
as well as an oral tablet.11 The effects of this drug also last for approximately 2-4 hours, which is
longer than oxytocin that lasts about 15-30 minutes, and misoprostol that lasts about 75 minutes.7
OBJECTIVE
The objective of this systematic review is to determine whether or not methylergometrine
is more effective than other uterotonic agents for the active management of the third stage of
labor.
METHODS
This review examined two randomized controlled trials and one prospective study, all of
which examined pregnant women at full term with a single uterine pregnancy who were in labor.
The intervention used was methylergometrine, which was compared to the experimental group
who received either oxytocin or misoprostol. Though the studies used different outcomes, the
intention was to determine the efficacy of methylergometrine compared to other uterotonic
agents. These outcomes were measured by mean amount of blood loss, incidence of postpartum
hemorrhage, and incidence of adverse side effects.
In order to find articles for this review, key words utilized include methylergometrine,
oxytocin, misoprostol, postpartum hemorrhage, and third stage of labor. All articles used were
published in English and found via searches on Medline and PubMed. These articles were then
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selected by the author based upon their relevance to the stated clinical question and whether or
not outcomes were applicable to patients. The inclusion criteria included randomized controlled
trials and one prospective study published after the year 2000 that studied full term pregnant
females with a single uterine pregnancy in the third stage of labor. Pregnant women who had to
undergo a cesarean section, induced labor, preterm labor, or multiple gestation were excluded.
Summary statistics used were means, standard deviations, p-values, and odds ratios.
Table 1: Demographics and Characteristics of Included Studies
Study

Type

#
Pts
438

Age
(Years)
Not
specified

Fujimoto8
(2006)

Prospective
Study

Singh9
(2009)

RCT

300

Not
specified

Vimala10
(2004)

RCT

120

Not
specified

Inclusion
Criteria
Pregnant
women in
spontaneous
onset of
labor,
healthy,
single
gestation
Pregnant
women ≥37
weeks of
gestation in
spontaneous
or induced
onset of labor
with healthy,
single
gestation

Pregnant
women ≥37
weeks of
gestation
with
spontaneous
onset of labor

Exclusion Criteria

W/D

Previous c-section,
history of antepartum
hemorrhage or
postpartum hemorrhage
in a previous pregnancy,
or contraindication for
receiving uterotonic
drugs.
Known hyper-sensitivity/
contraindication to
prostaglandins,
intrauterine fetal demise,
antepartum hemorrhage,
multiple pregnancy,
malpresentation, cardiac
disease, Rh- mother,
hypersensitive disorders,
hemoglobin < 7g/dl, or
use of oxytoxics until the
second stage of labor.
Use of oxytoxin to
augment or induce labor,
c-section deliveries,
grand multipara (parity
>5), gestation <37 weeks,
multiple gestation,
pregnancy-induced
hypertension, hemoglobin
concentration <8 gm/dl,
or known hypersensitivity to
prostaglandins

0

Interventions
Methylergometrine
200 μg (IV)

0

Methylergometrine
200 μg (IV)

0

Methylergometrine
200 μg (IV)
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OUTCOMES MEASURED
The outcomes measured were the incidence of postpartum hemorrhage despite the use of
prophylactic uterotonic agents as well as adverse effects of medication use. This was determined
by the difference of mean blood loss and whether or not the values were significant, as well as
clinical cases of postpartum hemorrhage. This allowed for determination as to whether or not
each agent was better at preventing significant amounts of blood lost. There was also analysis
regarding the adverse side effects of the medications. Patients reported several side effects,
including nausea, vomiting, and headache, though this review focused specifically on incidence
of subsequent nausea experienced by patients.8,9,10
RESULTS
The two randomized controlled trials and one prospective study used in this review all
compare the effectiveness of methylergometrine compared to another uterotonic agent, either
oxytocin or misoprostol. Efficacy of these medications was evaluated through incidence of
postpartum hemorrhage and adverse side effects of medication. The inclusion and exclusion
criteria were all comparable in these studies (Table 1), and all patients that entered the trial were
accounted for at the conclusion.8,9,10
In the randomized controlled trial performed by Vimala et al, 120 pregnant women were
randomized into two treatment groups. Use of IV methylergometrine was compared to
sublingual misoprostol during the third stage of labor. Both treatment groups had similar results
with regards to estimated blood loss and incidence of post partum hemorrhage, and the
differences in the data were not found to be statistically significant. With methylergometrine,
there were no cases of postpartum hemorrhage, whereas there were two cases after
administration of misoprostol amounting to 3.3% (p >0.05, CI = 90%) (Table 2).10
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Table 2: Methylergometrine vs. misoprostol during the third stage of labor (Vimala et al, 2004)10
Methylergometrine
Misoprostol
P value
Estimated Blood Loss (ml)
p > 0.05
170 ± 42
185 ± 56
Blood Loss ≥500ml
0%
3.3%
p > 0.05
Nausea
13.3%
6.6%
p > 0.05
In terms of adverse side effects, methylergometrine and misoprostol were once again
comparable with 13.3% and 6.6% incidences, respectively (p >0.05, CI = 90%) (Table 2). This
study showed that overall, there were no noteworthy differences between using
methylergometrine and misoprostol in terms of drug efficacy, and the discrepancies can be
attributed to random variance (Table 2). This suggests that the two are equally effective in the
management of postpartum hemorrhage during the third stage of labor. As seen in Tables 3, for
every 30 participants who were administered methylergometrine, there was one fewer incidence
of postpartum hemorrhage compared to those who were given misoprostol. However, for every
15 patients treated with methylergometrine, one additional would experience nausea (Table 4).10
Table 3: Methylergometrine vs. misoprostol comparison of incidence of postpartum hemorrhage
(Vimala et al, 2004)10
More episodes of postpartum
Relative Risk
Absolute Risk
Number
hemorrhage
Reduction
Reduction (ARR) Needed to
(RRR)
Treat (NNT)
Misoprostol:
Methylergometrine: EER – CER
EER – CER
1/ARR
Control Event
Experimental Event
CER
Rate (CER)
Rate (EER)
0.033
0
-1
-0.033
-30
Table 4: Methylergometrine vs. misoprostol comparison of incidence of nausea (Vimala et al,
2004)10
More episodes of nausea due to
Relative Risk
Absolute Risk
Number
medication
Increase (RRI)
Increase (ARI)
Needed to
Harm (NNH)
Misoprostol:
Methylergometrine: EER – CER
EER – CER
1/ARI
Control Event
Experimental Event
CER
Rate (CER)
Rate (EER)
0.066
0.133
1.015
0.067
15
Singh et al performed a randomized controlled trial that evaluated IV methylergometrine
against IV oxytocin, with 75 women recruited for each group. This study showed that oxytocin
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was more effective than methylergometrine at minimizing blood loss by measuring the mean
amount of blood loss after delivery. For those given oxytocin, blood loss was about 154.73ml,
compared to methylergometrine where blood loss was about 223.48ml (p <0.01; CI = 0.95)
(Table 5).9
Table 5: Methylergometrine vs. oxytocin during the third stage of labor (Singh et al, 2009)9
Methylergometrine
Oxytocin
P value
Mean Blood Loss (ml)
223.48
154.73
p <0.01
Although the study performed by the Singh et al did not include an analysis as to whether
or not incidences of postpartum hemorrhage were statistically significant, the data indicated that
for every 38 patients who were given prophylactic methylergometrine, there was one more
incidence of postpartum hemorrhage than those who were given prophylactic oxytocin (Table 6).
It was found that the only cases of blood loss exceeding 500ml were in those given
methylergometrine, with no incidence of postpartum hemorrhage in the group given oxytocin.9
Table 6: Methylergometrine vs. oxytocin comparison of incidence of postpartum hemorrhage
(Singh et al, 2009)9
More episodes of postpartum
Relative Risk
Absolute Risk
Number
hemorrhage due to medication
Increase (RRI)
Increase (ARI)
Needed to
Harm (NNH)
Oxytocin:
Methylergometrine: EER – CER
EER – CER
1/ARI
Control Event
Experimental Event
CER
Rate (CER)
Rate (EER)
0
0.027
N/A
0.027
38
In the prospective study carried out by Fujimoto et al, use of prophylactic IV
methylergometrine and IV oxytocin were examined. Although there were reported incidences of
postpartum hemorrhage with use of both drugs, methylergometrine administration resulted in
more cases. There was noted to be a statistically significant increase in incidence of postpartum
hemorrhage when methylergometrine was used compared to oxytocin at 18.6% and 7.3%,
respectively (OR 0.31, CI = 95%) (Table 7).8
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Table 7: Methylergometrine vs. oxytocin during the third stage of labor (Fujimoto et al, 2006)8
Methylergometrine
Oxytocin
Odds Ratio
Blood Loss ≥500ml
18.6%%
7.3%
0.31
Nausea
2.8%
1.2%
-Considering the results from the Fujimoto et al study, it can be established that for every
8 participants who was administered methylergometrine, there was one more incidence of
postpartum hemorrhage compared to those given oxytocin (Table 8). Furthermore, for every 63
patients treated with methylergometrine, one additional patient would also experience nausea
(Table 9). Though there is not a prominent difference in adverse side effects, the ability of
oxytocin to minimizing postpartum hemorrhage was shown to be greater.9
Table 8: Methylergometrine vs. oxytocin comparison of incidence of postpartum hemorrhage
(Fujimoto et al, 2006)8
More episodes of postpartum
Relative Risk
Absolute Risk
Number
hemorrhage
Increase (RRI)
Increase (ARI)
Needed to
Harm (NNH)
Oxytocin:
Methylergometrine: EER – CER
EER – CER
1/ARI
Control Event
Experimental Event
CER
Rate (CER)
Rate (EER)
0.073
0.186
1.55
0.133
8
Table 9: Methylergometrine vs. oxytocin comparison of incidence of nausea (Fujimoto et al,
2006)8
More episodes of nausea due to
Relative Risk
Absolute Risk
Number
medication
Increase (RRI)
Increase (ARI)
Needed to
Harm (NNH)
Oxytocin:
Methylergometrine: EER – CER
EER – CER
1/ARI
Control Event
Experimental Event
CER
Rate (CER)
Rate (EER)
0.012
0.028
1.33
0.016
63
DISCUSSION
Though studies by Singh et al and Fujimoto et al came to the conclusion that oxytocin
was more effective than methylergometrine in preventing postpartum hemorrhage, the contrast in
the numbers needed to harm indicates that there is an issue with consistency in the underlying
data.
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While the availability of methylergometrine is not an issue in the United States, it can be
in low resource countries. Much like oxytocin, methylergometrine is given intravenously, which
means that training is required for those who are tasked with administering it during labor.1
Though the studies utilized in this review did not address intramuscular or oral
methylergometrine, these are also options that are available. While injectable forms must be
refrigerated and shield against light, the oral tablet can be stored at room temperature, potentially
making it more accessible.11
This drug is used specifically for managing issues related to postpartum hemorrhage,
such as uterine atony and failure of the uterus to return to its normal size after the placenta is
delivered. As an ergot derivative, it works by increasing and sustaining smooth muscle
contraction in the uterus.11 The use of methylergometrine is contraindicated in patients with
hypertension,1 and consequently preeclampsia and eclampsia.7 It also should not be used in
those with coronary heart disease, as it increases the risk of vasospasm and thus myocardial
ischemia. Such vasoconstriction can also occur in the peripheral vascular system and lead to
ischemia and gangrene, known as ergotism where there is an overdose or chronic use of the drug.
This ergot toxicity is possible if methylergometrine is used in conjunction with potent CYP3A4
inhibitors as well, so it is not recommended if a patient is also taking macrolides, azole
antifungals, or protease inhibitors.11
There were limitations with this review due to inadequate randomized controlled trials
performed with regards to the clinical question. While standard of care uterotonic agents were
compared to methylergometrine, another randomized controlled trial would have provided more
valuable information than a prospective study. Moreover, all of the studies used had small
sample sizes. The treatment groups ranged from 60-82 patients, which does not provide a great
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deal of information. Due to this, there was quite a bit of variation in the data from one study to
the next.8,9,10
CONCLUSION
After reviewing the data from the three studies, it is inconclusive as to whether or not
methylergometrine is more effective than other uterotonic agents. Though both studies that
compared methylergometrine to oxytocin showed that its use resulted in more incidence of
postpartum hemorrhage, the underlying numbers showed quite a bit of discrepancy. The
numbers needed to harm in the Fujimoto study were far more drastic at one in every eight
patients resulting in postpartum hemorrhage (Table 8), as opposed to the Singh study where one
in every thirty eight had that outcome (Table 6).8,9 When comparing methylergometrine to
misoprostol in a randomized controlled study, the two appeared to be equivalent, but since it was
only one study, more evidence would be necessary to definitively come to such a conclusion.10
Future studies are indicated in order to determine whether or not methylergometrine is a
viable option for prevention of postpartum hemorrhage. Comparing oral methylergometrine with
other uterotonic agents may be a more valuable study, especially since it can be more easily used
and stored in countries with low resources where the gold standard treatment is not a viable
option.
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